Skip to main content
CONTEC MEDICAL SYSTEMS CO., LTD. logo

CONTEC MEDICAL SYSTEMS CO., LTD. — Investor Relations & Filings

Ticker · 300869 ISIN · CNE1000047F0 LEI · 6556007SL3V6YKCWVA55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 789 across all filing types
Latest filing 2022-06-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300869

About CONTEC MEDICAL SYSTEMS CO., LTD.

https://www.contecmed.com.cn

CONTEC Medical Systems Co., Ltd. focuses on the research, development, manufacturing, and distribution of medical electronic instruments. The product portfolio encompasses a wide range of diagnostic and monitoring solutions, including pulse oximeters, blood pressure monitors, electrocardiographs, ultrasound equipment, and multi-parameter patient monitors. Additionally, the company provides specialized devices such as fetal monitors, sleep apnea screening systems, and biochemical analyzers. By leveraging integrated research and large-scale production facilities, the organization delivers medical technology designed for clinical, hospital, and home healthcare environments. The company emphasizes technical innovation and adheres to international quality standards to ensure the precision and reliability of its medical hardware and software solutions.

Recent filings

Filing Released Lang Actions
康泰医学系统（秦皇岛）股份有限公司创业板向不特定对象发行可转换公司债券募集说明书摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书摘要" which translates to "Prospectus Summary" or "Offering Circular Summary" for a convertible bond issuance by 康泰医学系统（秦皇岛）股份有限公司. It contains detailed information about the convertible bond issuance, including compliance with regulatory requirements, credit rating, risk factors, profit distribution policy, and other disclosures related to the bond offering. The document is lengthy (15,000 characters) and contains substantive financial and operational details related to the bond issuance. This type of document is a capital/financing update related to fundraising activities through convertible bonds. It is not an annual report, earnings release, or other report types. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-06-28 Chinese
北京市长安律师事务所关于康泰医学系统（秦皇岛）股份有限公司向不特定对象发行可转换公司债券之法律意见书
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm (北京市长安律师事务所) regarding 康泰医学系统（秦皇岛）股份有限公司's issuance of convertible bonds to unspecified investors. It includes extensive legal analysis on the company's qualifications, issuance approvals, compliance with securities laws, corporate structure, independence, and other legal matters related to the bond issuance. The document references audit reports, annual reports, and regulatory approvals but is itself a legal opinion letter, not a financial report or earnings release. It is not a transcript, presentation, or announcement of voting results. The document is lengthy (15,000 characters) and contains substantive legal content, not merely an announcement or certification. Therefore, it fits best into the category of Regulatory Filings (RNS), as it is a regulatory legal opinion related to a financing activity but not a direct capital/financing update or a financial report.
2022-06-28 Chinese
第三届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 19th meeting of the 3rd Board of Directors of 康泰医学系统（秦皇岛）股份有限公司. It includes specifics about the issuance of convertible bonds, voting results, and procedural details. The content focuses on board decisions and approvals rather than financial results or reports. There is no indication that this is a full financial report, audit, or earnings release. The document is not a simple announcement of a report publication but a formal board meeting resolution announcement. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2022-06-28 Chinese
独立董事关于第三届董事会第十九次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion statement from independent directors regarding specific board meeting matters related to the issuance and listing of convertible bonds. It references regulatory approvals and compliance with laws but does not contain financial statements or detailed financial data. The document is focused on board-level approvals and opinions on financing activities, specifically the issuance of convertible bonds to unspecified investors and related procedural matters. This aligns with a Capital/Financing Update (CAP) rather than a full financial report or audit. The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is Capital/Financing Update (CAP).
2022-06-28 Chinese
第三届监事会第十次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at the 10th meeting of the 3rd Supervisory Board of Kangtai Medical System (Qinhuangdao) Co., Ltd. It details the approval of a convertible bond issuance plan, including issuance scale, pricing, interest rates, and related procedural matters. The document is an official meeting resolution announcement rather than a full financial report or detailed investor presentation. It primarily concerns capital raising activities through convertible bonds, which fits the category of Capital/Financing Update. The document length is 3460 characters, which is relatively short but contains substantive details about the financing plan, not just a brief notice or report publication announcement. Therefore, the best classification is Capital/Financing Update (CAP).
2022-06-28 Chinese
关于医疗器械注册证变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (569 characters) about a change in a medical device registration certificate issued by a regulatory authority (Hebei Provincial Drug Administration). It includes details about the product, registration number, approval date, and the nature of the change. It also contains a risk warning to investors. There is no financial data, no mention of financial results, no management discussion, no voting results, no share transactions, and no report attachments. The document is an official announcement related to regulatory compliance and product registration changes, not a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-06-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.